Good Morning America
Amid the growing popularity of drugs used for weight loss like Ozempic, Wegovy, Mounjaro and Zepbound, one question has remained for users, what happens if they were to stay on the drug for years? Now, a new study released earlier this month by Novo Nordisk, the maker of both Ozempic and Wegovy, is shedding light on what the long-term results look like for people on the weight loss medications. "This is the longest study we've conducted so far of semaglutide for weight loss," Martin Holst Lange, Novo Nordisk's head of development, told Reuters.